Faced with increasingly complex and challenging pressures, are we searching for a secret weapon that can precisely regulate the brain's emotional signals without interfering with daily cognition? Perhaps this innovative dipeptide anti-anxiety drug candidate, GB-115, is a brand-new key to exploring emotion regulation mechanisms in neuroscience.
What type of drug is GB-115
GB-115 powder is a novel investigational dipeptide anxiolytic. It is a selective antagonist (blocker) that blocks central cholecystokinin-1 (CCK₁) and CCK₂ receptors. Its chemical structure is generally described as N-(6-phenylhexanoyl)glycyl-L-tryptophanamide. Early pharmacological studies investigated it as a potential regulatory molecule within the cholecystokinin (CCK) receptor system. Research to date has primarily focused on its interactions with neurotransmitter pathways involved in mood and physiological regulation, particularly mechanisms related to anxiety regulation, stress response adaptation, and pain perception.
In preclinical animal models and basic laboratory studies, researchers have explored the potential anxiolytic-like properties of the compound and its effects on central nervous system signal transduction and neurochemical homeostasis. These studies aim to better understand how dipeptide compounds affect receptor-mediated signaling pathways and downstream neural activity. Preliminary results indicate potential biological activity; therefore, it is an experimental substance, and its use as a research chemical in in vitro or animal experiments is strictly limited. If you are interested in researching GB-115, please get in touch with Xi'an Sonwu.
What are the uses of GB-115
In research, GB-115 is primarily studied as a potential modulator of the cholecystokinin (CCK) receptor system. The CCK receptor system is a signaling pathway involved in mood regulation, stress response, and certain neurochemical processes in the central nervous system. Its chemical and pharmacological properties have attracted the attention of scientists studying how peptide molecules affect brain signaling and receptor-mediated activity.
In the laboratory and animal models, GB-115 has been used to explore its potential effects on anxiety-related behaviors, stress adaptation mechanisms, and pain perception pathways. Researchers are particularly interested in its potential anxiolytic-like activity and its role in regulating neurotransmitter homeostasis, which may contribute to a better understanding of how the brain processes stress and emotional responses. In addition to behavioral studies, the compound can also serve as a tool compound in basic neuropharmacology to study how small peptide structures interact with neural receptors and downstream signaling cascades.
This compound is currently in the early stages of experimental development. It is therefore used only in controlled laboratory settings, such as in vitro or animal experiments, to support ongoing research on neurobiological and peptide-based signaling mechanisms.
How does GB-115 work?
GB-115 is an experimental anti-anxiety dipeptide whose primary mechanism of action appears to be through the modulation of the cholecystokinin (CCK) signaling system in the brain. CCK is a neuropeptide involved in anxiety, stress response, panic-like response, and mood regulation. Studies have shown that it is a CCK receptor antagonist, meaning it can block some of the pro-anxiety effects of endogenous CCK signaling.
More specifically, GB-115 was developed as a reverse analogue of CCK-4, a peptide known to induce anxiety and panic-like responses. The compound has demonstrated anxiolytic activity in animal studies, including elevated cruciate maze and open field tests, by interfering with CCK-related pathways. Activation of CCK receptors can reduce or eliminate the anxiolytic effect of the compound, suggesting that the two compounds act on the same pharmacological target.
In addition to its anxiolytic effects, some preclinical studies have suggested that GB-115 may affect pain perception through the interaction between CCK and the opioid system. However, its anxiolytic effect does not appear to be related to direct activation of opioid receptors. Experimental data have also reported mild antidepressant-like effects and potential cognitive benefits, without the sedative effects commonly found in benzodiazepines. Therefore, the mechanism of action of it is thought to be through modulating CCK receptors to reduce anxiety-related neural signaling, thereby alleviating emotional stress responses while potentially maintaining alertness and cognitive function.
What are the side effects of GB-115
GB-115 is an experimental dipeptide compound related to the cholecystokinin (CCK) system. Currently, there is no human clinical data to support its safety and side effects. Referring to similar CCK receptor antagonists and related peptide compounds (such as CCK-1 or CCK-2 receptor antagonists), these substances mainly act on the central nervous system and gastrointestinal signaling pathways. Therefore, certain neurobehavioral and physiological regulatory effects are usually observed in animal and basic research.
In the nervous system, CCK-related compounds may affect anxiety levels, stress responses, and arousal states, exhibiting varying degrees of sedation-like or mood-regulating effects. However, the results differ in different models, and even opposite reactions may occur. At the physiological level, since CCK is involved in appetite regulation and digestive function, these compounds may also affect gastrointestinal motility and eating behavior.
Overall, the effects of experimental compounds related to the CCK system are complex and exhibit individual variability.
If you would like to inquire about the price of GB-115 powder or other product information, please contact Xi'an Sonwu directly.
Email: sales@sonwu.com
Reference：[1]: https://pubmed.ncbi.nlm.nih.gov/17523442/?utm_source=chatgpt.com
https://www.merckmillipore.com/BG/en/tech-docs/paper/298019?utm_source=chatgpt.com